Pay in 4 interest-free payments of $6.31 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Findings: RCTSTEP 3 Trial - Wegovy vs Placebo for Weight Loss in Overweight Adults Without DM, JAMA (2021) [PubMed abstract] Design: Randomized, placebo-controlled trial (N=611 | length = 68 weeks) in overweight or obese adults (average weight 233 lbs | average BMI 38) without diabetes Treatment: Wegovy 2.4 mg sub-q once weekly vs Placebo
Research suggests BPC-157 may influence: Angiogenesis (formation of new blood vessels) Cellular signaling pathways Tissue repair mechanisms Inflammatory responses These findings are promising but should be interpreted cautiously
The FDA warns consumers that these products can be harmful and should not be used
The post asks patients to work with their provider to set the baseline monitoring schedule rather than pick one themselves
Children with allergies should work with pediatric allergists using established treatments
